PER1 Is a Prognostic Biomarker and Correlated With Immune Infiltrates in Ovarian Cancer

Mali Chen; Lili Zhang; Xiaolong Liu; Zhen Ma; Ling Lv

doi:10.3389/fgene.2021.697471

PER1 Is a Prognostic Biomarker and Correlated With Immune Infiltrates in Ovarian Cancer

Front Genet. 2021 Jun 17:12:697471. doi: 10.3389/fgene.2021.697471. eCollection 2021.

Authors

Mali Chen¹, Lili Zhang¹, Xiaolong Liu², Zhen Ma², Ling Lv¹

Affiliations

¹ Department of Obstetrics, Gansu Province Maternity and Child-Care Hospital, Lanzhou, China.
² Department of Surgical Oncology, Lanzhou University Second Hospital, Lanzhou, China.

Abstract

Background: Period circadian protein homolog 1 (PER1) is an important component of the biorhythm molecular oscillation system and plays an important part in the development and progression of mammalian cancer. However, the correlations of PER1 with prognosis and tumor-infiltrating lymphocytes in ovarian cancer (OV) remain unclear. Methods: The Oncomine and TIMER databases were used to examine the expression of PER1 in OV. Kaplan-Meier Plotter and PrognoScan were used to evaluate the relationship between PER1 and prognosis. Kaplan-Meier Plotter was used to analyze the relationships between PER1 and clinicopathological features of OV patients. The relationship between PER1 expression and immune infiltration in OV was investigated using the TIMER database and CIBERSORT algorithm. The STRING database was used to analyze PER1-related protein functional groups, the GeneMANIA online tool was used to analyze gene groups with similar functions to those of PER1, and Network Analyst was used to identify transcription factors that regulate PER1. The correlation between PER1 and immunoinvasion of OV was analyzed using TIMER. Finally, quantitative real-time polymerase chain reaction (qRT-PCR) was performed to detect PER1 expression. Results: PER1 was differentially expressed in different cancer tissues, and its expression in various OV subtypes was lower than that in normal ovarian tissue. OV patients with low PER1 expression had a reduced overall survival rate. Decreased PER1 expression in stage 1 and stage 1+2 OV patients was related to poor prognosis, while increased PER1 expression in stage 3+4 patients and TP53 mutation were related to poor overall survival and progression-free survival. We identified eight genes whose expression was strongly correlated with that of PER1, as well as four transcription factors that regulate PER1. In OV, PER1 expression levels were positively correlated with infiltration levels of cells including neutrophils, regulatory T cells, and M2 macrophages, and closely related to a variety of immune markers. Reduced expression of PER1 was significantly associated with poor overall survival. Conclusion: These findings suggest that PER1 could be used as a prognostic biomarker to determine prognosis and immune infiltration in OV patients.

Keywords: PER1; bioinformatics; diagnosis and prognosis biomarkers; immune infiltrates; ovarian cancer.